Inidascamine

Inidascamine (INNTooltip International Nonproprietary Name; developmental code names RL-007, FSV7-007) is an experimental drug which is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS).^{[1][3][4][5][6][2]} It is taken orally.^[1][2] The drug is said to act on the cholinergic, NMDA, and GABA_B receptor systems.^[1][5][2] Inidascamine is being developed by Recognify Life Sciences and atai Life Sciences.^[1][3] It was discovered via screening of compounds for effects on synaptic plasticity and cognition.^[2] The drug shows structural similarities to phenethylamines and amphetamines.^[7]

Inidascamine

Clinical data
Other names	RL-007; RL007; FSV7-007
Routes of administration	Oral[1][2]
Identifiers
IUPAC name (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one
CAS Number	903884-71-9
PubChem CID	11535990
ChemSpider	9710771
UNII	3LW01V88B7
ChEMBL	ChEMBL5095258
CompTox Dashboard (EPA)	DTXSID90238113
Chemical and physical data
Formula	C12H17N3O2
Molar mass	235.287 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CCN(C1)C(=O)[C@@H]([C@H](C2=CC=NC=C2)O)N
InChI InChI=1S/C12H17N3O2/c13-10(12(17)15-7-1-2-8-15)11(16)9-3-5-14-6-4-9/h3-6,10-11,16H,1-2,7-8,13H2/t10-,11+/m1/s1 Key:GRZMKKUGHIECFK-MNOVXSKESA-N

See also

• List of investigational antipsychotics